C
Gemini changed its name late last month to reflect its clinical genomics approach to identifying disease genes.
Separately, CuraGen expanded its drug discovery and pharmacogenomics collaboration with COR Therapeutics of South San Francisco. The companies will use CuraGen's PathCalling proteomics technology and bioinformatics systems to create an annotated database of protein-protein interactions derived from cardiovascular endothelial cells.